Sky News Network
No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • National
  • Culture
  • Science & Technology
  • Opinion
  • Sports
No Result
View All Result
Sky News Network
No Result
View All Result
Home Science & Technology

Russia’s claim of a successful COVID-19 vaccine doesn’t pass the ‘smell test,’ critics say

skynewsbyskynews
November 13, 2020
in Science & Technology
0
Russia’s claim of a successful COVID-19 vaccine doesn’t pass the ‘smell test,’ critics say

Coronavirus vaccine. A vaccine against COVID-19 Coronavirus in ampoules on aged wooden table

0
SHARES
11
VIEWS
Share on FacebookShare on TwitterWhatsapp

Another day, another promising COVID-19 vaccine? A Russian institute announced today its vaccine candidate has had remarkable success in an efficacy trial, just 2 days after the widely celebrated news from Pfizer and BioNTech that their vaccine had greater than 90% efficacy. The Russian report, however, is being met with raised eyebrows—and some outright guffaws.

MOSCOW, RUSSIA JUNE 18, 2020: Pictured in this video screen grab is a volunteer receiving a Russian-made polyvalent vector vaccine for COVID-19 as part of clinical trials at Sechenov First Moscow State Medical University. Lyophilised (freeze-dried) into a powder to make solutions for intramuscular injections, the vaccine was developed at Gamaleya Research Institute of Epidemiology and Microbiology. The trials have involved 38 volunteers, 18 of which received injections today, with the rest to follow next week. They are going to spend 28 days at the inpatient facility of the universitys Research and Practice Centre of Interventional Cardioangiology. Best quality available. Sechenov Medical University Press Office/TASS (Photo by Sechenov Medical University Press OfficeTASS via Getty Images)

In a press release, the Gamaleya National Center of Epidemiology and Microbiology in Moscow said an interim analysis of a large-scale trial underway in Russia had found 92% efficacy for its “Sputnik V” vaccine. The release quoted the Russian minister of health saying the results demonstrate that Sputnik V “is an efficient solution to stop the spread of coronavirus infection.” Yet it also noted the review covered just 20 total COVID-19 cases in the vaccinated and placebo groups—far too few for the claim be convincing, experts inside and outside of Russia say.
In contrast, they note, Pfizer and BioNTech analyzed 94 cases to make their efficacy claim, and other vaccinemakers plan to wait for at least 50 or more COVID-19 cases to accumulate in a trial to assess a candidate’s worth. “It’s very difficult to explain [the Gamaleya] announcement,” says Svetlana Zavidova, a Moscow-based lawyer who heads Russia’s Association of Clinical Trials Organizations and closely follows COVID-19 vaccine R&D in the country. “I’m afraid they looked at the results of Pfizer and added 2%.”
The claims don’t pass “the smell test,” adds Wayne Koff, who heads the nonprofit Human Vaccines Project, which is attempting to improve the design of future vaccines. (The Gamaleya media contact on the press release did not reply to Science’s request for an interview.)
The Gamaleya vaccine, made with support from the Russia Direct Investment Fund, uses two different shots in what’s known as a prime-boost scheme. Both shots rely on supposedly harmless adenoviruses as gene delivery “vectors”: Researchers have engineered them to hold the gene for the surface protein of SARS-CoV-2, the virus that causes COVID-19. The first shot used adenovirus 26 (Ad26) as the vector for the coronavirus surface protein, called spike, while the second used adenovirus 5 (Ad5). The 20 cases described in the press release were detected among more than 16,000 people in the 40,000-person study. Participants were evaluated for COVID-19 21 days after receiving the Ad26 shot, when they came to the trial site to received their Ad5 booster.
The U.S. Food and Drug Administration “wouldn’t have accepted a report on 20 cases,” says John Moore, a vaccine researcher at Weill Cornell Medical College. He regards the announcement as “Putinology,” referring to the Russian president. “Why is Russia doing this?” Moore asks. “It’s the international vaccine race. They want to be seen to be keeping up with their competitors in other countries. It’s clearly a rushed out announcement. But it doesn’t mean it’s wrong.”
The Gamaleya press release said the study had not found any serious side effects, but vaccine researcher Julie McElrath from the Fred Hutchinson Cancer Research Center says the Ad5 vector worries her. McElrath co-authored a commentary in The Lancet last month that raised concerns about using Ad5 as a vehicle for COVID-19 vaccines, because it was linked to a catastrophe in an HIV vaccine study 13 years ago. In that trial, vaccine recipients had higher rates of HIV infection than those in the placebo group; the Ad5 vector has become the leading suspect for the problem. “Certainly, we need multiple vaccine strategies to end the pandemic, so I look forward to seeing additional data after a longer time interval,” McElrath says.
One month before Sputnik V’s efficacy trial launched in September, the Gamaleya vaccine received a highly controversial approval from Russian regulatory authorities, which allowed it to be given to people outside of a clinical trial. The Gamaleya release says the vaccine has been used in “red zones” of Russian hospitals, which means health care workers and other high-risk groups. To date, the release says 10,000 people have received the vaccine under this authorization. “[T]he civil use of the vaccine out of clinical trials also confirmed the vaccine’s efficacy rate of over 90 percent,” the Gamaleya release says without offering any evidence to back this claim.
Koff, who for many years headed the AIDS vaccine division of the U.S. National Institutes of Health (NIH), did allow that the efficacy claim is an “interesting observation,” though one that is hard to evaluate because Gamaleya, like Pfizer and BioNTech, offered scant data to back up their press release. He also notes that neither the center nor the Russian government has tried to harmonize their vaccine push with international standards for efficacy trials and vaccine approvals.
Pfizer and BioNTech and many other companies have made their trial protocols public, but Gamaleya has not. Zavidova notes that she learned more about the details of Gamaleya’s study on a clinical trials website maintained by NIH than she did on a similar registry in Russia, which has “only the name of this protocol without any details.”
In the press release, Alexander Gintsburg, the head of the Gamaleya, promises “mass vaccination in Russia against COVID-19 in the coming weeks.” If the Gamaleya vaccine does become widely available, will Zavidova take it, given that the spread of COVID-19 has rapidly accelerated in Russia? “No,” she says. “I will wait a little bit more.”

Source: Agencies
Tags: corona vaccine
Plugin Install : Subscribe Push Notification need OneSignal plugin to be installed.
skynews

skynews

Related Posts

New method can stop cyberattacks in less than a second
Science & Technology

New method can stop cyberattacks in less than a second

June 21, 2022
Uganda, Kenya tech startups to battle other African giants for continental awards
Science & Technology

Uganda, Kenya tech startups to battle other African giants for continental awards

May 10, 2022
New science shows you can become younger by 30 years
Science & Technology

New science shows you can become younger by 30 years

May 5, 2022

Popular Stories

  • How corruption has eaten up Uganda’s water corporation

    How corruption has eaten up Uganda’s water corporation

    0 shares
    Share 0 Tweet 0
  • Uganda’s water boss lined up for sacking as wife shames minister in party elections

    0 shares
    Share 0 Tweet 0
  • NWSC Board probes Silver Mugisha as Museveni unleashes intelligence on water ministry

    0 shares
    Share 0 Tweet 0
  • Assassinations: who is spilling blood in Uganda, and why?

    0 shares
    Share 0 Tweet 0
  • How Ugandan brokers sealed Museveni, Ruto deal throwing Kenyatta, Odinga into chaos

    0 shares
    Share 0 Tweet 0

Archives

About Us

We are the leading online news publication in Uganda with authentic and reliable news.

LEARN MORE »

Recent News

  • Prince Charles represents Queen at Commonwealth meeting in Rwanda June 22, 2022
  • New method can stop cyberattacks in less than a second June 21, 2022
  • We all have to work together in DRC, Museveni tells EAC colleagues June 21, 2022

Quick Links

  • About us
  • Advertise
  • Careers
  • Contact Us

Address

UJA House, Bombo Rd,

Keti Falawo Zone, Kawempe Division

Kampala – Uganda

© 2020 – Sky News Network

No Result
View All Result
  • Home
  • Politics
  • News
  • Business
  • National
  • Sports
  • Science & Technology
  • Agriculture & African Medicine
  • Travel
  • Opinion

© 2020 Sky News Uganda

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.